BFM
RARX

Boothbay Fund Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Boothbay Fund Management’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-12,766
Closed -$286K – 976
2019
Q1 		$286K Sell
12,766
-9,913
-44% -$213K 0.03% 516
2018
Q4 		$413K Buy
22,679
+7,882
+53% +$124K 0.06% 312
2018
Q3 		$268K Buy
+14,797
New +$175K 0.03% 549

Other funds holding RARX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Boothbay Fund Management's RARX Position: Q2 2019 in Review

Boothbay Fund Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2019, closing a stake of 12,766 shares — an estimated $286K sold.

Boothbay Fund Management first reported a position in RARX in Q3 2018 and held it in 3 quarters. The position peaked at $413K in Q4 2018. 118 funds tracked by Wall St. Rank hold RARX as of Q2 2019.

  • Boothbay Fund Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Boothbay Fund Management sold 12,766 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2019, an estimated $286K.
  • Boothbay Fund Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q3 2018 and held it in 3 quarters.
  • Boothbay Fund Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $413K in Q4 2018.
  • 118 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2019.

Based on Boothbay Fund Management's 13F filing for Q2 2019, filed 14 Aug 2019.